Design and Evaluation of ACAFiB-APP, a clinical decision support system for anticoagulant considerations in patients with atrial fibrillation DOI Creative Commons
Ramin Ansari, Sorayya Rezayi, Ali Asghar Safaei

et al.

BMC Cardiovascular Disorders, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 8, 2025

Patients with atrial fibrillation are at risk for various complications, including thromboembolic events. This study involves developing and evaluating a Clinical Decision Support System (CDSS) to select appropriate anticoagulant drug, considering comorbidities, laboratory data, concurrent medications. The system is based on streamlined interpretation of the most recent globally accepted clinical guidelines. Primarily semi-structured interview regarding challenges in field thromboprophylaxis AF pharmacists cardiologists' needs practice was conducted. Then required data were extracted from latest guidelines confirmed by expert panel. Using Microsoft Visio software each scenario its corresponding rules modeled. Dart programming language, Flutter framework, Visual Studio editor used develop application. Finally, uMARS questionnaire evaluate application quality. selection anticoagulants reported be challenging domain 78.6% participants interview. According designed algorithms, developed using Asp.net SQL Server database platform. CDSS called ACAFiB-APP, which stands Anticoagulant Application. user goes through calculators obtains moreover, will choose one or more comorbidities/clinical scenarios. ACAFiB-APP represent proper options dosing related considerations. All sections received acceptable scores. facilitate informed complicated cases patient scenario. Not applicable.

Language: Английский

Discordance and Performance of the ARC-HBR and PRECISE-DAPT High Bleeding Risk Definitions After Coronary Stenting DOI Creative Commons
Carl-Emil Lim, Moa Simonsson, Björn Pasternak

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

The aim of the ARC-HBR (Academic Research Consortium for High Bleeding Risk) and PRECISE-DAPT (Predicting Complications in Patients Undergoing Stent Implantation Subsequent Dual Antiplatelet Therapy) score definitions high bleeding risk is to identify patients who would benefit from shorter or less intensive antiplatelet therapy after coronary stenting. this study was assess performance routine clinical practice. Using nationwide registers, all Stockholm, Sweden, were discharged stenting with dual (January 1, 2013, July 2018) included. categorized as according 2 tools, (BARC [Bleeding Academic Consortium] types 3-5 TIMI major minor) ischemic events (myocardial infarction stroke) within 1 year discharge assessed. Of 7,562 patients, proportions 27% (2,004 7,562) using definition 38% (2,894 score; 22% (1,696 had discordant categorization comparing tools. vs without higher BARC type 3 5 (1-year 7.1% 2.3%; HR: 3.21; 95% CI: 2.47-4.17) (7.8% 2.8%; 2.96; 2.31-3.79). minor (4.4% 2.1%; 2.17; 1.63-2.89) (6.2% 2.7%; 2.38; 1.85-3.05). underestimated across almost levels (median absolute difference between observed predicted 1-year 1.1%; Q1-Q3: 0.8%-1.4%). There substantial discordance score. Both tools identified at increased risk, but those also risk. Guideline-recommended may not be generalizable patient populations, refined scoring systems are needed.

Language: Английский

Citations

1
Multisociety endorsement of the 2024 European guideline recommendations on coronary revascularization DOI Creative Commons

Víctor Dayan,

Joseph F. Sabik, Minoru Ōno

et al.

Brazilian Journal of Cardiovascular Surgery, Journal Year: 2025, Volume and Issue: 40(1)

Published: Jan. 1, 2025

Language: Английский

Citations

1
Evaluate the effect of virtual nurse-guided discharge education app on disease knowledge and symptom response in patients following coronary events DOI Creative Commons
Ling Zhang, Robyn Gallagher,

Huiyun Du

et al.

International Journal of Medical Informatics, Journal Year: 2025, Volume and Issue: 196, P. 105818 - 105818

Published: Feb. 4, 2025

Language: Английский

Citations

1
Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States DOI Creative Commons
Leo F. Buckley,

Bhavya Chebrolu,

Mohsen Al Zaria

et al.

JACC Advances, Journal Year: 2025, Volume and Issue: 4(3), P. 101622 - 101622

Published: Feb. 15, 2025

In the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) coronary artery disease trials, low-dose colchicine decreased risk of major adverse cardiovascular events (MACEs) by 23% to 31% beyond statin therapy with a strong safety profile. The number MACE potentially preventable widespread use in United States remains uncertain. objective this study was estimate current potential impact on outcomes. We first calculated new users before after publication at an integrated health care system southeastern New England from 2018 2023. Second, we estimated avoidable MACEs using incidence rates relative reduction trial nationally representative National Health And Nutrition Examination Survey study. From January December 2019 (before publication), varied between 126 151 every 6 months. 2020 June 2023, increased 141 181 months (<1% adults Mass General Brigham). Among 9.2 million stable States, adding standard medical management is prevent 226,000 over 3-year period. Adding may

Language: Английский

Citations

1
Design and Evaluation of ACAFiB-APP, a clinical decision support system for anticoagulant considerations in patients with atrial fibrillation DOI Creative Commons
Ramin Ansari, Sorayya Rezayi, Ali Asghar Safaei

et al.

BMC Cardiovascular Disorders, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 8, 2025

Patients with atrial fibrillation are at risk for various complications, including thromboembolic events. This study involves developing and evaluating a Clinical Decision Support System (CDSS) to select appropriate anticoagulant drug, considering comorbidities, laboratory data, concurrent medications. The system is based on streamlined interpretation of the most recent globally accepted clinical guidelines. Primarily semi-structured interview regarding challenges in field thromboprophylaxis AF pharmacists cardiologists' needs practice was conducted. Then required data were extracted from latest guidelines confirmed by expert panel. Using Microsoft Visio software each scenario its corresponding rules modeled. Dart programming language, Flutter framework, Visual Studio editor used develop application. Finally, uMARS questionnaire evaluate application quality. selection anticoagulants reported be challenging domain 78.6% participants interview. According designed algorithms, developed using Asp.net SQL Server database platform. CDSS called ACAFiB-APP, which stands Anticoagulant Application. user goes through calculators obtains moreover, will choose one or more comorbidities/clinical scenarios. ACAFiB-APP represent proper options dosing related considerations. All sections received acceptable scores. facilitate informed complicated cases patient scenario. Not applicable.

Language: Английский

Citations

1